全文获取类型
收费全文 | 28002篇 |
免费 | 2750篇 |
国内免费 | 585篇 |
专业分类
耳鼻咽喉 | 178篇 |
儿科学 | 1046篇 |
妇产科学 | 823篇 |
基础医学 | 681篇 |
口腔科学 | 201篇 |
临床医学 | 2185篇 |
内科学 | 2553篇 |
皮肤病学 | 149篇 |
神经病学 | 254篇 |
特种医学 | 584篇 |
外国民族医学 | 64篇 |
外科学 | 3097篇 |
综合类 | 3479篇 |
现状与发展 | 2篇 |
预防医学 | 633篇 |
眼科学 | 110篇 |
药学 | 2275篇 |
18篇 | |
中国医学 | 813篇 |
肿瘤学 | 12192篇 |
出版年
2024年 | 64篇 |
2023年 | 354篇 |
2022年 | 837篇 |
2021年 | 1122篇 |
2020年 | 993篇 |
2019年 | 903篇 |
2018年 | 926篇 |
2017年 | 1007篇 |
2016年 | 1239篇 |
2015年 | 1166篇 |
2014年 | 1771篇 |
2013年 | 2239篇 |
2012年 | 1599篇 |
2011年 | 1795篇 |
2010年 | 1357篇 |
2009年 | 1407篇 |
2008年 | 1350篇 |
2007年 | 1508篇 |
2006年 | 1370篇 |
2005年 | 1120篇 |
2004年 | 908篇 |
2003年 | 809篇 |
2002年 | 721篇 |
2001年 | 658篇 |
2000年 | 537篇 |
1999年 | 506篇 |
1998年 | 409篇 |
1997年 | 409篇 |
1996年 | 297篇 |
1995年 | 269篇 |
1994年 | 257篇 |
1993年 | 175篇 |
1992年 | 145篇 |
1991年 | 139篇 |
1990年 | 117篇 |
1989年 | 107篇 |
1988年 | 91篇 |
1987年 | 82篇 |
1986年 | 65篇 |
1985年 | 83篇 |
1984年 | 72篇 |
1983年 | 61篇 |
1982年 | 44篇 |
1981年 | 50篇 |
1980年 | 47篇 |
1979年 | 40篇 |
1978年 | 40篇 |
1977年 | 26篇 |
1976年 | 29篇 |
1975年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Palat Balachandran M.S. M.Ch. Shaleen Agarwal M.S. M.Ch. Narendra Krishnani M.D. Chandra M. Pandey Ph.D. Ashok Kumar M.S. M.Ch. Sadiq S. Sikora M.S. Rajan Saxena M.S. Vinay K. Kapoor M.S. 《Journal of gastrointestinal surgery》2006,10(6):848-854
The aim of this study was to examine the predictors of long-term survival (>24 months) in patients with gall bladder cancer.
A retrospective review of 117 cases of gall bladder cancer resected between 1989 and 2000. The resections included 80 simple
cholecystectomies and 37 extended procedures. Patients with survival >24 months (n=44) were compared with those having survival
<24 months (n=73) for 17 prognostic factors. Overall median survival was 16 months with a 5-year survival of 27%. T status
(P=.000) and adjuvant chemoradiotherapy (P=.001) were independent predictors of long-term survival. Survival advantage was
seen in T3N+ve disease (P=.007) with extended procedures. Complete (R0) resection was attained in 30 patients with a 5-year
survival advantage of 30% as compared with incomplete (R1) resection (P=.0002). Adjuvant chemoradiotherapy improved survival
in simple cholecystectomy group (P=.0008) but no advantage was seen after extended procedures. Stage III (P=.001) and node-positive
disease (P=.0005) had significant benefit with adjuvant therapy. Poor differentiation and vascular invasion were associated
with poor long-term survival. R0 resection was associated with prolonged survival. Extended procedures improved survival in
patients with T3N+ve disease. Addition of chemoradiotherapy made significant improvement in long-term survival in stage III
and node-positive lesions and in patients undergoing simple cholecystectomy. R0 resection predicted long-term survival in
gall bladder cancer. T3 N+ve disease had better survival after extended procedures. Adjuvant chemoradiotherapy improved survival
in stage III and node-positive disease. Poor differentiation and vascular invasion were adverse predictors of survival. 相似文献
22.
Kiyotaka YOH Makoto TAHARA Kenji KAWADA Hirofumi MUKAI Masanobu NAKATA Kuniaki ITOH Mitsuhiko KAWASHIMA Hideki NISHIMURA Ryuichi HAYASHI Takashi OGINO Hironobu MINAMI 《Asia-Pacific Journal of Clinical Oncology》2006,2(4):180-184
Background: Olfactory neuroblastoma is a rare sino‐nasal tumor arising from the olfactory epithelium and is often characterized by local invasion or metastasis. The role of chemotherapy in the treatment of this tumor is unclear. The purpose of this study was to review our institution’s experience of chemotherapy for advanced or recurrent olfactory neuroblastoma. Methods: Twenty‐one patients with histologically proven olfactory neuroblastoma were treated at our institution between 1992 and 2002. Twelve of these patients received chemotherapy in the setting of unresectable or recurrent disease and were retrospectively reviewed for clinical characteristics, treatment outcome or survival. Results: Eight patients of the 12 patients received cisplatin‐based chemotherapy and the remaining four patients received chemotherapy consisting of docetaxel plus irinotecan (three patients) or cyclophosphamide, doxorubicin, and vincristine (1 patient). A partial response was achieved in five patients, with an overall response rate of 42%, although the chemotherapeutic regimens were heterogeneous. Two partial responses were obtained among the three patients who received docetaxel plus irinotecan. The response rate to chemotherapy was 83% in the younger age group (<40 years), as opposed to 0% in the older age group (≥40 years), and the difference between the two groups was statistically significant (P = 0.02). Conclusion: Our study indicated that olfactory neuroblastoma would be sensitive to chemotherapy, especially with young patients. Docetaxel plus irinotecan has the possibility of showing favorable response, and warrants further investigation. 相似文献
23.
A. GURBUZ A. KARATEKE C. KABACA G. KIR & E. CETINGOZ 《International journal of gynecological cancer》2006,16(S1):307-312
Abstract. Gurbuz A, Karateke A, Kabaca C, Kir G, Cetingoz E. Peritoneal tuberculosis simulating advanced ovarian carcinoma: is clinical impression sufficient to administer neoadjuvant chemotherapy for advanced ovarian cancer? Int J Gynecol Cancer 2006; 16(Suppl. 1): 307–312.
Peritoneal tuberculosis mimics advanced ovarian cancer because of the similarities in clinical signs and symptoms such as ascites, pelvic and abdominal pain and mass, and elevation of serum CA125 level. We have presented four cases of peritoneal tuberculosis that underwent exploratory laparotomy for suspected advanced ovarian cancer during a 3-year period. Definitive diagnosis of tuberculosis was performed at laparotomy in all the cases. The frozen-section analysis seems to be the gold standard in the differential diagnosis. In view of these data, clinical diagnosis of advanced ovarian cancer is not sufficient for administering neoadjuvant chemotherapy. Cytologic or pathologic findings must be consistent with ovarian cancer for candidates who are being considered for neoadjuvant chemotherapy. 相似文献
Peritoneal tuberculosis mimics advanced ovarian cancer because of the similarities in clinical signs and symptoms such as ascites, pelvic and abdominal pain and mass, and elevation of serum CA125 level. We have presented four cases of peritoneal tuberculosis that underwent exploratory laparotomy for suspected advanced ovarian cancer during a 3-year period. Definitive diagnosis of tuberculosis was performed at laparotomy in all the cases. The frozen-section analysis seems to be the gold standard in the differential diagnosis. In view of these data, clinical diagnosis of advanced ovarian cancer is not sufficient for administering neoadjuvant chemotherapy. Cytologic or pathologic findings must be consistent with ovarian cancer for candidates who are being considered for neoadjuvant chemotherapy. 相似文献
24.
J. M. Falletta B. Cushing S. Lauer B. Bell D. H. Mahoney R. Castleberry R. A. Krance 《Investigational new drugs》1990,8(2):167-170
Summary We conducted a phase I clinical study of aziridinylbenzoquinone (Diaziquone, AZQ) given as a 4 hour infusion weekly × 4. Forty-five children with recurrent acute leukemia and 33 children with various advanced solid tumors participated. Severe myelosuppression was the dose limiting toxic effect, occurring in all patients at the upper dose levels. Gastrointestinal and hepatic toxicities were infrequent and not severe. No allergic reactions occurred. Objective tumor regression was noted in 3 of 25 patients with a CNS tumor and in 6 of 45 patients with acute leukemia. For phase II trials the recommended dosage of Diaziquone given by this schedule is 18 mg/M2×4 for patients with a solid tumor, and is 30 mg/M2/week × 4 for children with acute leukemia. 相似文献
25.
本文报道了我院收治的卵巢恶性畸胎瘤31例,随访中2例失访,随访率为93.53%。并讨论了卵巢恶性畸瘤的治疗方式为手术加联合化疗,对年轻的I期患者可行患侧单侧附件切除术,术后化疗极为重要。化疗方法采用VAC或PVB方案联合化疗,本文还 影响预后的重要因素为临床分期期和病理学特点. 相似文献
26.
分析原发性腹膜后恶性肿瘤12例。83%以腹块和腹痛为主要症状,体征中腹块占91.5%,以恶性淋巴瘤居首位占61%。全组完全切除率为58%,行脏器联合切除占25%。完全切除加放疗、化疗3年存活率为28.5%,部分切除及活检未给其它治疗者5例预后差,均1年内死亡,差别显著。 相似文献
27.
Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas 总被引:1,自引:0,他引:1
H. von Holst E. Knochenhauer H. Blomgren V. P. Collins L. Ehn M. Lindquist G. Norén C. Peterson 《Acta neurochirurgica》1990,104(1-2):13-16
Summary Eight patients with malignant gliomas verified on CT scan, received an intravenous injection of 50 mg of Adriamycin R, 24 hours prior to surgical removal of the tumour. Peroperatively, both tumour and surrounding tissue specimens were obtained for determination of the tissue concentrations of Adriamycin and its reduced metabolite Adriamycinol. It was found that Adriamycin could be detected in tumour tissue from all patients. The concentration varied between 0,9 and 4,6 nmol/g tissue. In contrast, Adriamycin could only be detected in surrounding brain tissue from one patient.In anin vitro study a human malignant glioma cell line (U-251 MG) was exposed to various concentrations of Adriamycin for 24 hours. It was found that an intracellular drug concentration above 30 nmol/g cells caused a concentration dependent inhibition of cell growth. Thus, it is likely that the poor effect of Adriamycin on patients with malignant gliomas is due to an ineffective drug accumulation in the tumour tissue. 相似文献
28.
Summary Intracavitary application of ultrasound was first performed for diagnostic purposes in 1967; since that time, it has been
more and more widely used. As far as the gastrointestinal tract is concerned, endoscopically controlled ultrasonic probes
provide visualization of the various layers of the intestinal wall. It is therefore possible to describe lesions of the esophagus,
stomach, and the rectum with regard to their nature and depth of infiltration. Furthermore, periesophageal and perigastric
organs can be visualized. It has become evident that endosonography is particularly important for pretherapeutic staging of
tumors of the esophagus, stomach, and rectum. Here prospective comparative studies confirm the superiority of this new diagnostic
procedure when compared to the methods available to date. 相似文献
29.
长春瑞滨加异环磷酰胺加顺铂治疗晚期非小细胞肺癌98例临床疗效观察 总被引:2,自引:0,他引:2
吴海默 《中国肿瘤临床与康复》2005,12(4):338-339
目的观察长春瑞滨(NVB)、异环磷酰胺(IFO)、顺铂(PDD)三药联合(NIP)治疗晚期非小细胞肺癌的疗效和毒性.方法共收治ⅢB~Ⅳ期非小细胞肺癌98例,其中鳞癌51例,腺癌42例,大细胞癌5例.ⅢB期59例,Ⅳ期39例.初治71例,复治27例.方案:NVB 25 mg/m2静滴,第1,8天;IFO 1.5 g/m2,静滴,第1~3天;PDD 30 mg/m2,静滴,第1~3天.4周为一周期.结果 CR 1例,PR 44例,NC 45例,PD 8例,总有效率(CR PR)为45.9%.中位缓解期8个月,中位生存期11个月,1年生存率为48.0%.骨髓抑制为剂量限制性毒性,其中Ⅲ~Ⅳ度占40.8%.结论 NIP方案是治疗晚期非小细胞肺癌有效且安全的方案. 相似文献
30.
善存片联合健脾理气中药预防肿瘤患者化疗所致口腔溃疡的临床观察 总被引:1,自引:0,他引:1
目的观察在全身化疗前应用善存片联合健脾理气中药对肿瘤患者口腔溃疡的预防作用。方法将66例肿瘤患者随机分配为治疗组和对照组,每组33例。在全身静脉化疗前3天开始,治疗组每天口服善存片1片及健脾理气中药1剂,对照组服用维生素B:治疗,两组服药化疗后10天为1个疗程。每周期化疗结束后统计口腔溃疡的发生率,共4周期。结果治疗组口腔溃疡的发生率显著降低(P〈0.01)。结论善存片联合健脾理气中药可有效预防及治疗肿瘤患者化疗所致的口腔溃疡。 相似文献